Results 291 to 300 of about 100,641 (375)

A case report of multiple system atrophy-mimics: Importance of comprehensive evaluation in suspected familial cases. [PDF]

Medicine (Baltimore)
Jeong C, Farrer M, Khurana V, Kim HJ.
europepmc   +1 more source

Novel approaches for drug development against chronic primary pain: A systematic review

British Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus, Éva Borbély, Andreas Goebel, Ralf Baron, Zsófia Hajna, Zsuzsanna Helyes   +5 more
wiley   +1 more source

Levodopa-induced dyskinesia in Parkinson's disease: an updated review of pharmacological treatments. [PDF]

Front Aging Neurosci
Chen F, Zhou C.
europepmc   +1 more source

Duodenal levodopa/carbidopa infusion therapy in patients with advanced Parkinson’s disease leads to improvement in caregivers’ stress and burden

, 2012
Diego Santos‐García, M. J. Añón, L. Fuster‐Sanjurjo, Raúl de la Fuente‐Fernández   +3 more
openalex   +2 more sources

Non‐motor Symptom Scales in Pediatric Movement Disorders: A Call for Diagnostic‐Specific Tools

Movement Disorders, EarlyView.
Clément Desjardins, Christelle Nilles, Hortensia Gimeno, Kathryn J. Peall, Davide Martino, Tamara Pringsheim, Emmanuel Roze   +6 more
wiley   +1 more source

Vesicular glutamate transporter VGLUT2 expression emerges in substantia nigra dopamine neurons in mouse models of parkinsonism in the absence of neurodegeneration

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Subsets of midbrain dopamine (DA) neurons express the vesicular glutamate transporter VGLUT2 and can release the excitatory neurotransmitter glutamate. VGLUT2+ DA neurons of the substantia nigra pars compacta (SNc) were shown to be more resistant to neurodegeneration in animal models of Parkinson's disease (PD ...
Sivakumar Srinivasan, Christian Pifl, Thomas Steinkellner   +2 more
wiley   +1 more source

Cortical beta power modulation is asymmetric and reduced during movement execution and inhibition in Parkinson's disease. [PDF]

Neurobiol Dis
Deligani RJ, Opri E, Risk BB, Goldstein F, Factor SA, Higginbotham LA, Swann NC, Miocinovic S.   +7 more
europepmc   +1 more source

Percutaneous Endoscopic Gastro-Jejunostomy (PEGJ): Could Drug Administation be the Only Indication for Insertion? The Levodopa/Carbidopa Infusion Treatment Experience. A Retrospective Evaluation of the Method

, 2015
Vassilios Tzias, Andreas Koutsoumpas, Georgios Chrysakopoulos, Georgia Barla, Pantelis Stathis, Maria Maltezou, Chryssa Kakou   +6 more
openalex   +1 more source

Matsupexole: A novel nonergot dopamine receptor agonist with sustained efficacy in a rat model of Parkinson's disease and limited off‐target activity

British Journal of Pharmacology, EarlyView.
Background and Purpose Dopamine receptor agonists, particularly targeting the dopamine D2L receptor (D2LR), have been used to treat Parkinson's disease (PD). However, valvular heart disease and somnolence, mainly caused by activating the serotonin 5‐HT2B receptor (5‐HT2BR) and dopamine D3 receptor (D3R), respectively, currently challenge their clinical
Takayuki Suzuki, Fumiki Oana, Masaki Oota, Yuma Handa, Osamu Kaminuma   +4 more
wiley   +1 more source

Two novel variants of VPS13C gene related Parkinsonism: A case report and literature review. [PDF]

Medicine (Baltimore)
Jiang Y, Fan C.
europepmc   +1 more source